Recent advancements of bortezomib in acute lymphocytic leukemia treatment (Q26829613)

Qi Chen

series ordinal

2

1 reference

language of work or name

1 reference

2013

1 reference

1 reference

129

1 reference

issue

4

1 reference

page(s)

207-14

1 reference

Biology of acute lymphoblastic leukemia (ALL): clinical and therapeutic relevance

cites work

1 reference

Treatment of acute lymphoblastic leukemia

21 January 2018

1 reference

Recent research advances in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

Treatment of adult acute lymphoblastic leukemia

21 January 2018

1 reference

Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.

21 January 2018

1 reference

Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia

21 January 2018

1 reference

Relapsed acute lymphoblastic leukemia: current status and future opportunities

21 January 2018

1 reference

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

21 January 2018

1 reference

Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study

21 January 2018

1 reference

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy

21 January 2018

1 reference

Bortezomib for the treatment of mantle cell lymphoma

21 January 2018

1 reference

Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy

21 January 2018

1 reference

Bortezomib: a review of its use in patients with multiple myeloma

21 January 2018

1 reference

Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia

21 January 2018

1 reference

Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells

21 January 2018

1 reference

Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells

21 January 2018

1 reference

Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium

21 January 2018

1 reference

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

21 January 2018

1 reference

Phase I study of bortezomib in refractory or relapsed acute leukemias

21 January 2018

1 reference

A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.

21 January 2018

1 reference

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.

21 January 2018

1 reference

A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias

21 January 2018

1 reference

Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells.

21 January 2018

1 reference

Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells

21 January 2018

1 reference

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia

21 January 2018

1 reference

Activating Notch1 mutations in mouse models of T-ALL.

21 January 2018

1 reference

Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

Notch1 augments NF-kappaB activity by facilitating its nuclear retention

21 January 2018

1 reference

Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia.

21 January 2018

1 reference

The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia.

21 January 2018

1 reference

Acute lymphoblastic leukemia in elderly patients: a single institution's experience

21 January 2018

1 reference

Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors

21 January 2018

1 reference

Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker

21 January 2018

1 reference

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

The true face of JNK activation in apoptosis

21 January 2018

1 reference

The critical role of JNK in the ER-mitochondrial crosstalk during apoptotic cell death

21 January 2018

1 reference

The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway

21 January 2018

1 reference

Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress

21 January 2018

1 reference

Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.

21 January 2018

1 reference

The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia

21 January 2018

1 reference

21 January 2018

Proteasome inhibitors

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

1 reference

PubMed publication ID

23295437

1 reference